ICICI Ventures, IFC may exit Bharat Biotech; transaction may value company at 1000 crore
Investment banker Avendus has been mandated by ICICI Ventures to find suitors and the initial process has begun, sources in the know said.
“It is true that they want to exit because the fund is closing but they have been very happy with us. But I don’t know anything about the timeline or valuation,” Krishna Ella, chairman and managing director of Bharat Biotech said.
Investment banker Avendus has been mandated by ICICI Ventures to find suitors and the initial process has begun, sources in the know said. On the valuation expectations, Ella said: “For me valuation has no meaning at all. I don’t understand on what basis they have arrived at this figure.”
Set up in 1996, Bharat Biotech International is a privately held biotech firm and is jointly promoted by the husband and wife duo of Dr Krishna Ella and Suchitra Ella. The company has an annual turnover of Rs 350 crore.
Bharat Biotech develops and manufactures affordable next generation vaccines and bio-therapeutics at its facility at Genome Valley on Hyderabad’s outskirts adjacent to ICICI Ventures’ knowledge park.
The company recently created quite a stir in the market when it announced that it would be developing the world’s cheapest rotavirus vaccine at $1 a dose for the public markets as against $8 per dose being supplied by multi national companies to the public markets and at around $60 a dose in private markets.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.